The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Saha Saurabh since 2021.
This trader's CIK number is 1861926.
At the time of last reporting, Saha Saurabh was the Chief Executive Officer of Centessa Pharmaceuticals Plc. (stock ticker symbol CNTA).
Also see all insider trading activities at Centessa Pharmaceuticals Plc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | CNTA | 0 | $0 | 385,000 | $5,640,547 | 165,000 | $635,250 |
| 2024 | CNTA | 0 | $0 | 575,000 | $9,529,421 | 300,000 | $1,751,998 |
| 2022 | CNTA | 15,000 | $94,980 | 0 | $0 | 0 | $0 |
| 2021 | CNTA | 23,000 | $282,463 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-21 | CNTA | Option Ex | 55,000 | 3.85 | 211,750 |
| 2025-07-21 | CNTA | Sale | 55,000 | 15.92 | 875,600 |
| 2025-06-20 | CNTA | Option Ex | 55,000 | 3.85 | 211,750 |
| 2025-06-20 | CNTA | Sale | 55,000 | 12.63 | 694,815 |
| 2025-05-20 | CNTA | Option Ex | 55,000 | 3.85 | 211,750 |
| 2025-05-20 | CNTA | Sale | 55,000 | 12.71 | 699,105 |
| 2025-04-21 | CNTA | Sale | 14,656 | 12.29 | 180,107 |
| 2025-04-22 | CNTA | Sale | 40,344 | 12.43 | 501,475 |
| 2025-03-20 | CNTA | Sale | 55,000 | 16.69 | 918,060 |
| 2025-02-20 | CNTA | Sale | 55,000 | 16.23 | 892,705 |
| 2025-01-21 | CNTA | Sale | 55,000 | 15.98 | 878,680 |
| 2024-12-20 | CNTA | Sale | 55,000 | 17.44 | 959,035 |
| 2024-12-06 | CNTA | Sale | 87,496 | 18.46 | 1,615,263 |
| 2024-12-06 | CNTA | Option Ex | 87,496 | 5.84 | 510,976 |
| 2024-11-25 | CNTA | Option Ex | 299 | 5.84 | 1,746 |
| 2024-11-25 | CNTA | Sale | 299 | 18.23 | 5,450 |
| 2024-11-22 | CNTA | Sale | 1,671 | 18.24 | 30,479 |
| 2024-11-21 | CNTA | Option Ex | 3,511 | 5.84 | 20,504 |
| 2024-11-20 | CNTA | Sale | 55,000 | 16.89 | 928,730 |
| 2024-11-22 | CNTA | Option Ex | 1,671 | 5.84 | 9,758 |
| 2024-11-21 | CNTA | Sale | 3,511 | 18.24 | 64,030 |
| 2024-11-13 | CNTA | Option Ex | 32,023 | 5.84 | 187,014 |
| 2024-11-13 | CNTA | Sale | 32,023 | 18.28 | 585,412 |
| 2024-10-23 | CNTA | Sale | 2,592 | 15.31 | 39,696 |
| 2024-10-22 | CNTA | Sale | 30,203 | 15.67 | 473,160 |
| 2024-10-21 | CNTA | Sale | 22,205 | 15.80 | 350,861 |
| 2024-09-20 | CNTA | Sale | 55,000 | 16.53 | 908,985 |
| 2024-09-10 | CNTA | Sale | 175,000 | 16.52 | 2,891,874 |
| 2024-09-10 | CNTA | Option Ex | 175,000 | 5.84 | 1,022,000 |
| 2024-08-23 | CNTA | Sale | 46,651 | 12.30 | 573,900 |
| 2024-08-20 | CNTA | Sale | 4,169 | 12.32 | 51,370 |
| 2024-08-21 | CNTA | Sale | 3,674 | 12.24 | 44,988 |
| 2024-08-22 | CNTA | Sale | 506 | 12.23 | 6,188 |
| 2022-06-24 | CNTA | Buy | 10,000 | 4.63 | 46,280 |
| 2022-02-02 | CNTA | Buy | 5,000 | 9.74 | 48,700 |
| 2021-11-16 | CNTA | Buy | 23,000 | 12.28 | 282,463 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Saha Saurabh (Chief Executive Officer of Centessa Pharmaceuticals Plc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.